Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Corporate Update (May 2013)

57 slides from Sucampo Pharmaceuticals's corporate update, May 20, 2013

  1. Slide 1: AMITIZA (lubiprostone) OIC Indication Update

    AMITIZA® (lubiprostone) OIC Indication Update Hard Rock Hotel, Orlando, Florida May 20, 2013

  2. Slide 2: Introduction and Forward-Looking Statements

    Looking Statements Stanley G. Miele President, Sucampo Pharma Americas and SVP, Sales and Marketing 2

  3. Slide 3: Introduction and Forward-Looking Statements

    Introduction and Forward-Looking Statements Stanley G. Miele Company Update Stanley G. Miele Mechanism of Action Review Jack D. Wood, PhD Clinical Data Overview Taryn R. Joswick Clinical Practice Overview Brooks D. Cash, MD Marketing Overview Greg A. Deener Closing Remarks Stanley G. Miele 3

  4. Slide 4: Forward-looking statements

    This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set fo

  5. Slide 5: Company Update

    Stanley G. Miele President, Sucampo Pharma Americas and SVP, Sales and Marketing 5

  6. Slide 6: AMITIZA US Update

    • Market is still growing and addition of OIC provides tangible benefit: • Q1 2013 Net Sales up 7% YoY • First sale of OIC triggers $10M milestone payment from partner Takeda • Building on legacy of more than 7M prescriptions over 7 years • Growth trajectory expected to continue • Minimal losses fro

  7. Slide 7: Priority Review: What does this mean for Sucampo?

    • A Priority Review designation is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists • We have succeeded where others have failed • Safety concerns impeded other companies’ attempts to break into OIC market; mu-opioid−receptor agonist comp

  8. Slide 8: Review of Mechanism of Action

    Review of Mechanism of Action Jackie D. “Jack” Wood, MSc, PhD, AGAF Professor of Physiology & Cell Biology and Internal Medicine 8

  9. Slide 9: Enteric Nervous System is a Brain-in-the-Gut

    Enteric Nervous System is a Brain-in-the-Gut Integrated Neural Circuits 1. Program Library 2. Feedback Control 3. Reflexes 4. Information processing Big Brain Brain-In-The- Gut (100 Million Neurons) ENS (Little Brain) Lonitudinal Muscle Ganglion Fiber Tracts Menteric Plexus 9

  10. Slide 10: Mucosal Secretion: Enteric Nervous Control

    Mucosal Secretion: Enteric Nervous Control Central Nervous system Enteric nervous system Sensory Neurons Synaptic Circuits Information Processing Reflexes program Library Motor Neurons musculature Secretory Glands Blood Vasculature Organized Gi Behavior Secretion Propulsive motility Blood Flow 10

  11. Slide 11: Intestinal Propulsive Motility Requires a Functioning Enteric Nervous System

    Intestinal Propulsive Motility Requires a Functioning Enteric Nervous System: Enteric Nervous System 11

  12. Slide 12: Enteric Nervous System (cont'd): Tetrodotoxin

    Enteric Nervous System (cont’d) Intestinal Propulsive Motility Requires a Functioning Enteric Nervous System: TETRODOTOXIN 12

  13. Slide 13: Enteric Secretomotor Neurons

    Enteric Secretomotor Neurons Secretomotor Neuron Excitatory Receptor (Ach or VIP) Secretory Gland (e.g., Crypt of lieberkuhn) H2O, NaCI, HCO3 and Mucus Secretion 13

  14. Slide 14: Ussing Chambers are Used to Study Mucosal Secretion

    14 Ussing Chambers are Used to Study Mucosal Secretion

  15. Slide 15: Ussing Chamber Examples: Pharmacological Analysis

    15 Ussing Chamber Examples: Pharmacological Analysis Example-1 (short-Circuit Current) Tetrodotoxin (1 nM) Example-2 Carbachol (3NM) Morphine (10 nM) Lubi. (30 NM)

  16. Slide 16: Human Small Intestine (Jejunum) Lubiprostone Response

    Human Small Intestine (Jejunum) ISC (nA/cm3) Serosal Side (EC50=65.2nm) Mucosal Side (EC50 = 74.6 nM) N = 11 Preparations Lubiprostone (nM) 0.1 1.0 10 100 1000 16

  17. Slide 17: Tetrodotoxin: Neural Blockade

    Tetrodotoxin: Neural Blockade Secretomotor Neuron Excitatory Receptor (Ach or VIP) Secretory Gland Opioid Receptor Opiates/ Opioids Morphine Oxycodone Hydrocodone Methadone Blood Flow Vasodilation Vasoldilation Arteriole H2O, NaCI HCO3 Mucus Secretion 17

  18. Slide 18: Opiates and Opioid Drugs Suppress Secretomotor Neurons

    18 Opiates and Opioid Drugs Suppress Secretomotor Neurons Secretomotor Neuron Excitatory Receptor (Ach or VIP) Secretory Gland Opioid Receptor Opiates/ Opioids Morphine Oxycodone Hydrocodone Methadone Blood Flow Vasodilation Vasoldilation Arteriole H2O, NaCI HCO3 Mucus Secretion

  19. Slide 19: Lubiprostone Reverses Morphine-Induced Suppression of Secretion

    19 Lubiprostone Reverses Morphine-Induced Suppression of Secretion Guinea Pig small Intestine Serosal Side IC 50 = 96 nM N = 4 Setups; 6 Animals

  20. Slide 20: Lubiprostone Reverses Morphine-Induced Suppression of Secretion (cont'd)

    20 Lubiprostone Reverses Morphine-Induced Suppression of Secretion (cont’d) Morphine (10nM) Lubi. (30nM) Human Small Intestine (Jejunum) N=7 Gastric Bypass Patients 12 Preparations Control DMSO Lubi. (30nM)

  21. Slide 21: Lubiprostone Reverses Morphine-Induced Suppression of Fecal Output

    21 Lubiprostone Reverses Morphine-Induced Suppression of Fecal Output Conscious Mouse Fecal Pellets (mg) Time (Minutes)DMSO (2.6%) Morphine (3mg/kg) Lubiprostone (0.2mg/kg)

  22. Slide 22: Conclusions

    1. Opiate/opioid drugs induce constipation by suppression of neurogenic mucosal secretion and with reduced liquidity of the contents in the intestinal lumen as a consequence. 2. Opiate/opioid drugs reduce intestinal liquidity by suppressing the excitability of secretomotor neurons in the brain-in-th

  23. Slide 23: Pipeline and R&D Update

    Pipeline and R&D Update Taryn R. Joswick Vice President, Clinical Development 23

  24. Slide 24: Global AMITIZA Approvals and Regulatory Filings

    Global AMITIZA Approvals and Regulatory Filings Japan CC (2012) UK CIC (2012) OIC (filed) US CIC (2006) IBS-C (2008) OIC Approved (April 2013) Switzerland CIC (2009) OIC (filed) AMITIZA has been used for >7 y with 7 million prescriptions by patients suffering from chronic idiopathic constipation and

  25. Slide 25: OIC Development Program Overview

    • Three 12-week pivotal studies conducted in patients with diagnosis of OIC due to chronic use of opioids for non-cancer pain • Two studies met respective primary efficacy endpoints, while one did not demonstrate statistically significant difference in favor of AMITIZA • One long-term safety extensi

  26. Slide 26: OIC Label Overview: Indications and Usage

    OIC Label Overview: Indications and Usage Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults(1.1) Treatment of opioid-induced constipation in adults with chronic, non-cancer pain (1.2) Treatment of irritable bowel syndrome with constipation

  27. Slide 27: OIC Label Overview: Adverse Reactions

    OIC Label Overview: Adverse Reactions 27 Table 2: Percent of Patients with Adverse Reactions (OIC Studies) System/ Adverse Reaction1 Placebo N = 632 % Amitiza 24 mcg Twice Daily N + 860 % Gastrointestinal disorders Nausea Diarthea Abdominal pain Flatulence Abdominal distension Vomiting Abdominal dis

  28. Slide 28: OIC Label Overview: Adverse Reactions (cont'd)

    OIC Label Overview: Adverse Reactions (cont’d) The most common adverse reaction (incidence > 4%) in OIC were nausea and diarrhea. Nausea: Approximately 11% of patients who received Amitiza 24 mcg twice daily experienced nausea; 1% of patients had svere nausea and 2% of patients discontinued treatmen

  29. Slide 29: OIC Label Overview: Drug Interactions

    OIC Label Overview: Drug Interactions 7 Drug interactions No in vivo drug-drug interaction studies have been performed with Amitiza Based upon the results of in vitro human microsome studies, there is low likeihood of pharmacokinetic drug-drug interactions. Invitro studies using human liver microsom

  30. Slide 30: Overall Spontaneous Bowel Movement Response in OIC Patients

    n = 431 n = 418 18.9 15.4 27.1 24.3 0 5 10 15 20 25 30 Study 1 Study 2 Placebo Lubiprostone P = 0.03* Proportion of Responders, % = 8.2 = 8.9 *Statistically significant (P ≤0.05) See Reference 2 30 Over all Spontaneous Bowel Movement (“SBM”) Response in OIC Patients

  31. Slide 31: Competitive Landscape

    Bevenopran Adolor/Cubist Phase 3 Phase 2 Marketed Nalcol S.L.A. Pharma AG Naloxegol AstraZeneca, Nektar Relistor (PO) Progenics/Salix TD1211 Theravance / GlaxoSmithKline AMITIZA Sucampo Filed Relistor (SC) Progenics/Salix EXPECT NO MARKET CHALLENGE FOR AMITIZA USE FOR OIC NON-CANCER PATIENTS FOR UP

  32. Slide 32: Competitive Landscape (cont'd)

    Competitive Landscape (cont’d) “…the Division has communicated that it believes a very large, well-controlled, chronic administration trial will have to be conducted to assess the safety of any mu-opioid antagonist prior to market approval for the treatment of patients with OIC who are taking opioid

  33. Slide 33: Summary and Outlook for AMITIZA

    • Well positioned to serve expanding population of patients with CIC, OIC and IBS-C • 7M prescriptions used over past 7 years with favorable benefit-risk profile • AMITIZA currently approved for three indications with additional LCM opportunities: • Expand global approvals and launches for AMITIZA w

  34. Slide 34: AMITIZA in Clinical Practice

    AMITIZA in Clinical Practice Brooks D. Cash, MD, FACG, AGAF Professor of Medicine, USUHS Deputy Commander for Medicine, Walter Reed National Military Medical Center Bethesda, MD, USA 34

  35. Slide 35: CIC / OIC & IBS-C: Criteria Comparison

    CIC / OIC & IBS-C: Criteria Comparison Functional Constipation ROME III Criteria 1. Must include 2 or more of the following: a. straining with 25% of defecations c. Sensation of Incomplete evacuation for at least 25% of defecations d. sensation of anorectal obstruction for at least 25% of defecation

  36. Slide 36: Patient descriptions: broad set of complaints

    Patient descriptions Patients with constipation have a broad set of complaints See Reference 4 36 Constipaion Symptoms: Physician vs. Patient Perception Straining 81 hardor lupy stools 72 Incomplete emptying 54 Stool cannot be passed 39 Abdominal fullness or bloating 37 <3 BM per week Physicians thi

  37. Slide 37: Causes of Constipation

    Constipation Gastrointestinal Colorectal: neoplasm, ischemia, volvulus, megacolon, diverticular disease Anorectal: prolapse, rectocele, stenosis, megarectum Drugs Opiates Antidepressants Anticholinergics Antipsychotics Antacids (Al, Ca) Ca channel blockers Iron supplements Metabolic/ Endocrine Hyper

  38. Slide 38: AMITIZA Clinical Overview

    AMITIZA Clinical Overview See References 2, 7-9 Lubiprostone : A GI system targeted bicyclic functional fatty acid activates Chloride channel (CIC-2) in the apical membrane of the GI epithelium Causing… Increased chloride secretion leading to… increased intaluminal fluid in the gut facilitation… Int

  39. Slide 39: AMITIZA Safety Profile

    • No gender restriction in CIC or OIC; approved for use in women with IBS-C in US • No black box warning • Well tolerated in short-term (4 weeks) and long-term (6-12 months) trials; no limitation on duration of use • Proven long-term exposure in CIC and IBS-C • Rapid onset in CIC: 57%−63% of patient

  40. Slide 40: Constipation in Advanced Disease

    • Estimates of the frequency of opioid induced constipation vary from 15–90%2 • Opioids increase chloride absorption and delay GI motility • OIC is the most common reason for discontinuation of opioid therapy • Impact of OIC: • Creates more distress for pain patients (often more significant that pri

  41. Slide 41: Challenges Inherent in OIC

    • Improve Awareness of Pathophysiology and Costs of OIC • Patients • Clinicians • Caregivers • Promote Screening for OIC • Proactive intervention • Repeated assessment • Promote Patient Education • Increase Awareness of Treatment Options for OIC • Benefits of therapy/Risks of failure to intervene •

  42. Slide 42: Treatment Priorities

    Treatment Priorities Treatment decisions should be based on: Degree to which symptoms affect patient’s life Results achieved with agents in the past Patient preference Clinical judgment Aim to relieve constipation symptoms, not necessarily increase the number of BMs Identifying the underlying cause

  43. Slide 43: Oral Treatment Options

    Bulk laxatives • Insoluble fiber: bran 20 gm/day • Soluble fiber: methylcellulose, psyllium Osmotic laxatives • Polyethylene glycol (PEG) 21 gm/day • Lactulose and sorbitol (carbohydrate laxatives that are poorly absorbed by gut) • Phosphate or magnesium Oral Treatment Options * FDA approved for OIC

  44. Slide 44: AMITIZA Approval for OIC

    • sNDA received fast-track approval • Lack of effective alternatives • Prevalence of condition • Burden of condition • Based on results of two phase 3 trials and longer term open label study • Counteracts the electrolyte absorbent effects of opioids AMITIZA Approval for OIC 44

  45. Slide 45: Role of AMITIZA in Clinical Practice

    • Proven efficacy in clinical trials and durable clinical experience • AGA Technical Review 2013 • Trial of bulking agents, lifestyle modifications first line therapy • Pharmacologic therapy appropriate for failures to above modifications • More likely to be required in drug-induced and slow-transit

  46. Slide 46: AMITIZA in GI Practice Pearls

    • Set realistic goals; target most bothersome symptoms • Administer with food (8-24 mcg BID) • Once daily dosing effective in many patients • Rapid onset of effect, typically within first 24 hours • Eliminate other laxative therapies prior to initiating AMITIZA • Equally effective across sexes, age

  47. Slide 47: Marketing Overview

    Marketing Overview Greg A. Deener Senior Vice President, Marketing Strategy and Implementation 47

  48. Slide 48: Chronic Opioid Patient Market

    4.5M Chronic Opioid Patients 3.8M with Non-Cancer Pain 2.3M with Moderate Constipation .26M with Severe Constipation Market: 2.5M Constipation is the longest lasting common side effect of chronic opioids; dose adjustment of opioids does not reduce See Reference 14-15 48

  49. Slide 49: AMITIZA in OIC

    • Currently, 80% of the market is stool softeners, OTC laxatives and prescription PEGs • Use of AMITIZA is limited in OIC due to lack of awareness that AMITIZA is effective in OIC and low awareness among pain specialists • Build awareness that AMITIZA is the first and only medicine for OIC among PCP

  50. Slide 50: AMITIZA OIC Launch: Build on Strengths and Heritage

    AMITIZA OIC Launch: Build on Strengths and Heritage 7M prescriptions over 7 years AMITIZA MiraLax Provides Sustained Relief 74.7 67.7 Relieves Bloating/Discomfort 72.2 61.8 Relieves Abdominal Pain 71.5 62.4 Low Incidence of Diarrhea 64.1 57.8 83.0% 8.4% 8.5% 37.6% 47.5% 14.9% 0% 20% 40% 60% 80% 100%

  51. Slide 51: Opioid Chronic Pain Prescriptions by Specialty

    Three-Quarters of Opioid Chronic Pain Prescriptions are in Primary Care and Pain Specialists Primary Care 44% Ind. NP/PA 10% Pain Specialist 23% All Others 23% Long-Acting Opioid Prescriptions by Specialty See Reference 15 51

  52. Slide 52: Strategy to Grow AMITIZA

    Strategy to Grow AMITIZA Target Goal PCPs who already write AMITIZA +OIC Pain Specialists Gis Target Goal PCP Non-Writers +CIC +IBS-C +OIC 52

  53. Slide 53: OIC: Increase Prescriptions in Current Writers and Relaunch to Non-Writers

    63.6% 71.8% 27.3% 22.7% 13.6% 25.5% 0% 10% 20% 30% 40% 50% 60% 70% 80% CIC IBS-C OIC AMITIZA PEGs Top of Mind (Unaided) Awareness of AMITIZA vs. PEGs Among Primary Care Writers of AMITIZA 33.3% 44.2% 10.0% 40.0% 18.3% 45.8% 0% 10% 20% 30% 40% 50% 60% 70% 80% CIC IBS-C OIC AMITIZA PEGs Top of Mind (U

  54. Slide 54: AMITIZA is Building on Strengths

    AMITIZA offers a simple solution for chronic constipation conditions Safe Effective No Hassle • This is an opportunity to grow the entire AMITIZA brand • Full OIC launch by commercialization partner Takeda on May 13, 2013 with resources necessary to gain awareness among both PCPs and pain specialist

  55. Slide 55: Closing Remarks

    Closing Remarks Stanley G. Miele President, Sucampo Pharma Americas and SVP, Sales and Marketing 55

  56. Slide 56: References

    1. Online Physician Community, February 2013 2. AMITIZA PI 3. Longstreth GF, et al. Gastroenterology. 2006;130:1480-1491. 4. Pare et al, Am J Gastroenterol 2001; 96: 3130–7 5. Candelli M, et al. Hep-Gastro. 2001;48:1050. 6. Locke GR, et al. Gastroenterology. 2000;119:1766. 7. Johanson, MedGenMed 200

  57. Slide 57: References (placeholder)

    Other Placeholder: Online Physician Community, February 2013 AMITIZA PILongstreth GF, et al. Gastroenterology. 2006;130:1480-1491.Pare et al, Am J Gastroenterol 2001; 96: 3130–7Candelli M, et al. Hep-Gastro. 2001;48:1050.Locke GR, et al. Gastroenterology. 2000;119:1766.Johanson, MedGenMed 2007 9: 25

Sucampo Pharmaceuticals — Corporate Update (May 2013) on 6ix